Health Catalyst, Inc.

NasdaqGS:HCAT 주식 리포트

시가총액: US$131.7m

Health Catalyst 향후 성장

Future 기준 점검 0/6

Health Catalyst 의 수익은 연간 16% 감소할 것으로 예상되는 반면, 연간 수익은 92.2% 로 증가할 것으로 예상됩니다. EPS는 연간 89.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 2.5% 로 예상됩니다.

핵심 정보

92.2%

이익 성장률

89.49%

EPS 성장률

Healthcare Services 이익 성장19.1%
매출 성장률-16.0%
향후 자기자본이익률2.51%
애널리스트 커버리지

Low

마지막 업데이트12 Aug 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Aug 05

HCAT: Cleaner Execution And Sector Rebound Will Shape 2026 Reset

Health Catalyst's analyst price targets have shifted higher into a $2 to $3 range, reflecting revised fair value estimates and updated models as analysts weigh sector rebounds, expectations for cleaner quarters, and company specific factors like the pending Vitalware sale. Analyst Commentary Bullish analysts covering Health Catalyst are pointing to a tighter, higher price target range as they refresh models ahead of upcoming earnings reports.
내러티브 업데이트 • Jul 21

HCAT: Cost Cuts And Cleaner Quarters Will Guide A Cautious Reset

Health Catalyst's analyst price targets have moved higher, with recent updates pointing to a range of around $1.75 to $3 as analysts factor in a lower discount rate, slightly less revenue decline, and expectations for cleaner quarters ahead. Analyst Commentary Recent Street research on Health Catalyst highlights a mix of optimism around the updated models and caution around execution risks into upcoming quarters.
내러티브 업데이트 • Jul 07

HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further

Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.
내러티브 업데이트 • Jun 23

HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround

Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.
내러티브 업데이트 • Jun 05

HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset

Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.
내러티브 업데이트 • May 09

HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround

Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.
내러티브 업데이트 • Apr 24

HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further

Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.
내러티브 업데이트 • Apr 08

HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk

Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.
내러티브 업데이트 • Mar 25

HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound

Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.
내러티브 업데이트 • Mar 11

HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound

Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.
내러티브 업데이트 • Feb 24

HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential

Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.
분석 기사 • Feb 13

Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...
내러티브 업데이트 • Feb 10

HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound

Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.
내러티브 업데이트 • Jan 27

HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential

Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.
내러티브 업데이트 • Jan 10

HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility

Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.
내러티브 업데이트 • Dec 26

HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility

Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.
내러티브 업데이트 • Dec 11

HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential

Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.
내러티브 업데이트 • Nov 27

HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook

Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.
내러티브 업데이트 • Nov 13

HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance

Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.
분석 기사 • Oct 28

Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet

You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...
내러티브 업데이트 • Aug 30

Modular AI Solutions Will Transform Value-Based Healthcare

Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.
분석 기사 • Aug 13

Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price

NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...
내러티브 업데이트 • Aug 10

Modular AI Solutions Will Transform Value-Based Healthcare

Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.
분석 기사 • Aug 04

Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jun 10

Health Catalyst: Ignite Platform Is A Growth Catalyst

Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking Alpha
분석 기사 • May 09

Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
User avatar
새로운 내러티브 • Mar 30

Ignite Transition And Recent Acquisitions Will Expand Global Footprint

Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.
Seeking Alpha • Mar 25

Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook

Summary Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. Risks include potential revenue stall, macroeconomic challenges, and stock price volatility, but I remain cautiously optimistic, looking for a breakout to add to my position. Read the full article on Seeking Alpha
분석 기사 • Mar 08

Take Care Before Jumping Onto Health Catalyst, Inc. (NASDAQ:HCAT) Even Though It's 27% Cheaper

To the annoyance of some shareholders, Health Catalyst, Inc. ( NASDAQ:HCAT ) shares are down a considerable 27% in the...

이익 및 매출 성장 예측

NasdaqGS:HCAT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2028222N/AN/AN/A1
12/31/2027206-39N/AN/A4
12/31/2026247-179N/AN/A4
6/30/2026292-265728N/A
3/31/2026302-265-319N/A
12/31/2025311-178-211N/A
9/30/2025316-108-33-13N/A
6/30/2025316-100-26-6N/A
3/31/2025311-73-145N/A
12/31/2024307-70-215N/A
9/30/2024302-79-16-1N/A
6/30/2024299-86-17-4N/A
3/31/2024297-106-31-17N/A
12/31/2023296-118-47-33N/A
9/30/2023290-124-44-29N/A
6/30/2023285-147-61-44N/A
3/31/2023282-148-59-42N/A
12/31/2022276-137-53-35N/A
9/30/2022272-151-47-30N/A
6/30/2022265-145-40-24N/A
3/31/2022254-147-34-19N/A
12/31/2021242-153-42-23N/A
9/30/2021230-147-39-17N/A
6/30/2021216-135-36-17N/A
3/31/2021200-126-29-13N/A
12/31/2020189-115-37-26N/A
9/30/2020179-86-39-35N/A
6/30/2020171-99-41-36N/A
3/31/2020165-181N/A-44N/A
12/31/2019155-241N/A-32N/A
9/30/2019148-304N/A-32N/A
6/30/2019141-282N/A-33N/A
3/31/2019127-190N/A-38N/A
12/31/2018113-114N/A-40N/A
12/31/201773-59N/A-37N/A

애널리스트 향후 성장 전망

수입 대 저축률: HCAT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: HCAT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: HCAT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: HCAT 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -16%).

고성장 매출: HCAT 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -16%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: HCAT의 자본 수익률은 3년 후 2.5%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/14 23:54
종가2026/08/14 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Health Catalyst, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Zhilin LongBerenberg
David LarsenBTIG
Richard CloseCanaccord Genuity